Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

[Business Wire] – Agios Pharmaceuticals, Inc. , a leader in the fields of cancer metabolism and inborn errors of metabolism, announced that data from its lead, first-in-class program AG-221 will be presented today at a Clinical Trials Symposium titled †more

View todays social media effects on AGIO

View the latest stocks trending across Twitter. Click to view dashboard

See who Agios is hiring next, click here to view